Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit
April 25 2019 - 12:00PM
Atossa Genetics Inc. (NASDAQ:
ATOS), a
clinical-stage biopharmaceutical company developing novel
therapeutics and delivery methods for breast cancer and other
breast conditions, announced that today Steven C. Quay, M.D.,
Ph.D., Atossa’s President and CEO, is providing an update on the
Company’s clinical programs at the Precision: Breast Cancer World
R&D Summit at 2:00 pm ET.
Dr. Quay’s presentation is titled, “A Twenty-First
Century Approach: From Primary Prevention to Intraductal
Immunotherapy,” and will include the following updates:
Ongoing Phase 2 Study: Dosing has
been completed in Atossa’s Phase 2 clinical study of topical
Endoxifen to reduce mammographic breast density. Analysis of
the results is underway and expected to be announced this
quarter.
Expanded Access Program: The first
safety end point has been successfully achieved in the FDA-approved
expanded access program using Atossa’s proprietary oral Endoxifen
to treat a single patient following breast cancer surgery. The
patient in this study continues to experience few side effects from
Endoxifen.
Intraductal Immunotherapy Program:
Atossa recently completed the first phase of a preclinical study
using Atossa’s proprietary intraductal delivery technology. Imaging
of the mammary ducts of mice showed that dye was successfully
dispersed throughout the mammary duct system. Based on these
encouraging results, Atossa is advancing to the next preclinical
phase which involves the intraductal administration of immune
modulating formulations. This preclinical work will form the basis
for advancing the intraductal delivery program into humans and to
ultimately deliver immunotherapy to treat breast cancer using
Atossa’s proprietary intraductal delivery technology.
About Precision: Breast Cancer World
R&D Summit
The Precision Breast Cancer World R&D Summit is
an exclusive, annual biopharma summit providing insights into the
research and development of cutting-edge treatments for Breast
Cancer and a networking forum for precision medicine leaders in
this space. From therapeutics to diagnostics, the summit brings
together scientists and business leaders from pharma, biotech and
academia, using extensive networking sessions to forge meaningful
collaborations. The discussion and presentations are based around
the latest trends in personalized medicine, using case studies
covering early discovery to clinical development.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage
biopharmaceutical company developing novel therapeutics and
delivery methods to treat breast cancer and other breast
conditions. For more information, please
visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release,
which Atossa undertakes no obligation to update, are subject to
risks and uncertainties that may cause actual results to differ
materially from the anticipated or estimated future results,
including the risks and uncertainties associated with any variation
between preliminary and final clinical results, actions and
inactions by the FDA, the outcome or timing of regulatory approvals
needed by Atossa including those needed to commence studies, lower
than anticipated rate of patient enrollment, estimated market size
of drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa's drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time. Atossa
Genetics Company Contact:
Atossa Genetics Inc. Kyle Guse CFO and General
Counsel Office: 866 893-4927 kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott Gordon CoreIR 377 Oak Street Concourse 2
Garden City, NY 11530 Office: 516 222-2560 scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024